[HTML][HTML] A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase

L Monovich, RB Vega, E Meredith, K Miranda, C Rao… - FEBS letters, 2010 - Elsevier
L Monovich, RB Vega, E Meredith, K Miranda, C Rao, M Capparelli, DD Lemon, D Phan…
FEBS letters, 2010Elsevier
Class IIa histone deacetylases (HDACs) repress genes involved in pathological cardiac
hypertrophy. The anti-hypertrophic action of class IIa HDACs is overcome by signals that
promote their phosphorylation-dependent nuclear export. Several kinases have been shown
to phosphorylate class IIa HDACs, including calcium/calmodulin-dependent protein kinase
(CaMK), protein kinase D (PKD) and G protein-coupled receptor kinase (GRK). However, the
identity of the kinase (s) responsible for phosphorylating class IIa HDACs during cardiac …
Class IIa histone deacetylases (HDACs) repress genes involved in pathological cardiac hypertrophy. The anti-hypertrophic action of class IIa HDACs is overcome by signals that promote their phosphorylation-dependent nuclear export. Several kinases have been shown to phosphorylate class IIa HDACs, including calcium/calmodulin-dependent protein kinase (CaMK), protein kinase D (PKD) and G protein-coupled receptor kinase (GRK). However, the identity of the kinase(s) responsible for phosphorylating class IIa HDACs during cardiac hypertrophy has remained controversial. We describe a novel and selective small molecule inhibitor of PKD, bipyridyl PKD inhibitor (BPKDi). BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes and concomitantly suppresses hypertrophy of these cells. These studies define PKD as a principal cardiac class IIa HDAC kinase.
Elsevier